High-throughput sequencing reveals Jatrorrhizine inhibits colorectal cancer growth by ferroptosis-related genes

• Published in: BMC medical genomics Vol. 16; no. 1; pp. 1 - 11
• Main Authors: Huang, Lingyu, Sha, Yu, Liang, Wenken, Mo, Chune, Li, Chunhong, Deng, Yecheng, Gong, Weiwei, Hou, Xianliang, Ou, Minglin
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 14-09-2023; BioMed Central; BMC
• Subjects: Analysis; Apoptosis; Cancer; Cancer therapies; Care and treatment; Cell growth; Chinese medicine; Colorectal cancer; Colorectal carcinoma; Development and progression; Drug therapy; Ferroptosis; Flow cytometry; Gene expression; Genes; Genetic aspects; Growth; Health aspects; High-throughput screening (Biochemical assaying); High-throughput sequencing; Intervention; Jatrorrhizine; MAP kinase; Medical prognosis; Metastasis; Methods; Next-generation sequencing; p53 Protein; Patients; Signal transduction; Software; Survival analysis; Tumor proteins; Wnt protein; China
• ISSN: 1755-8794; 1755-8794
• DOI: 10.1186/s12920-023-01619-3

Colorectal cancer is a malignant tumor that poses a serious threat to human health. The main objective of this study is to investigate the mechanism by which Jatrorrhizine (JAT), a root extract from Stephania Epigaea Lo, exerts its anticancer effects in colorectal cancer. We initially assessed the inhibitory properties of JAT on SW480 cells using MTT and cell scratch assays. Flow cytometry was employed to detect cell apoptosis. Differentially expressed genes were identified through high-throughput sequencing, and they were subjected to functional enrichment and signaling pathway analysis and PPI network construction. RT-qPCR was used to evaluate gene expression and identify critical differentially expressed genes. Finally, the function and role of differentially expressed genes produced by JAT-treated SW480 cells in colorectal cancer will be further analyzed using the TCGA database. Our study demonstrated that JAT exhibits inhibitory effects on SW480 cells at concentrations of 12.5[micro]M, 25[micro]M, 50[micro]M, and 75[micro]M without inducing cell apoptosis. Through high-throughput sequencing, we identified 244 differentially expressed genes. KEGG and GO analysis of high-throughput sequencing results showed that differentially expressed genes were significantly enriched in MAPK, Wnt, and P53 signaling pathways. Notably, JAT significantly altered the expression of genes associated with ferroptosis. Subsequent RT-qPCR showed that the expression of ferroptosis genes SLC2A3 and ASNS was significantly lower in JAT-treated SW480 cells than in the control group. Analysis by TCGA data also showed that ferroptosis genes SLC2A3 and ASNS were significantly highly expressed in COAD. The prognosis of SLC2A3 was significantly worse in COAD compared to the normal group. SLC2A3 may be a core target of JAT for the treatment of COAD. JAT can inhibit COAD growth by ferroptosis-related genes. And it is a potential natural substance for the treatment of COAD.